Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1) - Simon, JA; Anderson, RA; Ballantyne, E (Menopause, 2023)